Kodiak Sciences stock trades at 87.33 euros in late session
Published on 10/30/2026 at 19:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPipeline gives the stock context
- Kodiak Sciences is developing retinal medicines as a precommercial biotechnology company.
- Its lead program, Zenkuda, has completed five Phase 3 pivotal studies.
Kodiak Sciences stock traded at 87.33 euros on Lang & Schwarz at 19:40 CET on Friday, October 30, 2026. The late-session quote provides investors with a current reference for the company after the European trading day.
Pipeline gives the stock context
According to Kodiak Sciences investor relations, the company is a precommercial biotechnology business focused on retinal medicines. Its lead investigational medicine, Zenkuda, has completed five Phase 3 pivotal studies, and Kodiak plans to submit a multi-indication biologics license application in 2026.
The company also says KSI-501 met the primary endpoint in the Phase 3 DAYBREAK study and is being evaluated in the Phase 3 ALTO study. These programs remain central to the investment case because Kodiak has not yet commercialized a product.
Current quote for investors
Investors can follow the real-time quote of Kodiak Sciences stock for subsequent movements.
Kodiak Sciences stock at a glance
- Company: Kodiak Sciences Inc.
- ISIN: US50015M1099
- Trading symbol: KOD
- Listing: Nasdaq
- Lang & Schwarz quote: 87.33 euros at 19:40 CET on October 30, 2026
Broader US market coverage is available in the current market reports.
For more company-specific developments, see more news and analyses on Kodiak Sciences stock.
